Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander(Harvard University), Joyce M. Slingerland(University of Miami)
Cited by 417
Related Papers
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
|Cell|2014|798
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
|Oncogene|2014|264
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
|Journal of Clinical Oncology|2024|75
DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
|Clinical Cancer Research|2022|71
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
|Breast Cancer Research and Treatment|2013|58